IL-17, IL-23 and IL-12/23 biologics on every 2026 Florida Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in Florida cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
| Drug | Wellcare Classic$0.00/moS4802-083 | Wellcare Value Script$0.00/moS4802-146 | Humana Value Rx Plan$25.90/moS5884-190 | Humana Basic Rx Plan$92.70/moS5884-105 | SilverScript Choice$98.30/moS5601-022 | BlueMedicare Premier Rx$98.60/moS5904-001 | AARP Medicare Rx Saver from UHC$98.70/moS5921-356 | Humana Premier Rx Plan$115.90/moS5884-157 | AARP Medicare Rx Preferred from UHC$119.10/moS5921-383 | BlueMedicare Complete Rx$217.00/moS5904-002 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stelaraustekinumab | Not covered | Not covered | Tier 5PA26%QL 1.5/84d | Tier 5PA25%QL 1.5/84d | Tier 5PA25%QL 0.5/28d | Not covered | Not covered | Tier 5PA33%QL 1.5/84d | Not covered | Not covered |
| ustekinumab biosimilarsWezlana, Selarsdi, Pyzchiva and others | Not covered | Not covered | Tier 5PA26%QL 1.5/84d | Tier 5PA25%QL 1.5/84d | Tier 5PA25%QL 0.5/28d | Not covered | Not covered | Tier 5PA33%QL 1.5/84d | Not covered | Not covered |
| Wezlanaustekinumab-auub | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Selarsdiustekinumab-aekn | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Skyrizirisankizumab | Tier 5PA25%QL 6/365d | Tier 5PA25%QL 6/365d | Tier 5PA26%QL 2/84d | Tier 5PA25%QL 2/84d | Tier 5PA25%QL 6/365d | Tier 5PA25%QL 6/365d | Tier 5PA25%QL 1/28d | Tier 5PA33%QL 2/84d | Tier 5PA31%QL 1/28d | Tier 5PA25%QL 6/365d |
| Tremfyaguselkumab | Tier 5PA25%QL 2/28d | Tier 5PA25%QL 2/28d | Tier 5PA26%QL 3/84d | Tier 5PA25%QL 3/84d | Tier 5PA25%QL 1/28d | Tier 5PA25%QL 3/56d | Tier 5PA25% | Tier 5PA33%QL 3/84d | Tier 5PA31% | Tier 5PA25%QL 3/56d |
| Cosentyxsecukinumab | Tier 5PA25%QL 10/28d | Tier 5PA25%QL 10/28d | Tier 5PA26%QL 8/28d | Tier 5PA25%QL 8/28d | Not covered | Tier 5PA25%QL 8/28d | Tier 5PA25%QL 10/30d | Tier 5PA33%QL 8/28d | Tier 5PA31%QL 10/30d | Tier 5PA25%QL 8/28d |
| Taltzixekizumab | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Bimzelxbimekizumab | Not covered | Not covered | Not covered | Not covered | Tier 5PA25%QL 4/28d | Not covered | Not covered | Not covered | Not covered | Not covered |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.